Halozyme Therapeutics | HALO - Debt


Halozyme Therapeutics reported $2.14B in Debt for its fiscal quarter ending in March of 2026.





Debt Change Date
Acadia Pharmaceuticals USD 50.79M 1.39M Mar/2026
Agios Pharmaceuticals USD 35.74M 4.46M Mar/2026
Alnylam Pharmaceuticals USD 1.27B 5.33M Mar/2026
Amarin USD 0 0 Mar/2025
Amgen USD 57.32B 2.72B Mar/2026
Baxter International USD 9.69B 93M Mar/2026
Cara Therapeutics USD 0 0 Mar/2025
Cytokinetics USD 1.29B 4.48M Mar/2026
DBV Technologies USD 6.1M 2.49M Mar/2026
Eli Lilly USD 43.37B 867M Mar/2026
Halozyme Therapeutics USD 2.14B 2.01M Mar/2026
Intrexon USD 0 13.82M Jun/2024
Ionis Pharmaceuticals USD 1.91B 425.5M Jun/2026
MannKind USD 330.96M 36.48M Mar/2026
Minerva Neurosciences USD 0 0 Sep/2024
Nektar Therapeutics USD 0 0 Jun/2022
Pfizer USD 63.73B 231M Mar/2026
Rigel Pharmaceuticals USD 59.69M 90K Jun/2024
United Therapeutics USD 200M 100M Mar/2025
Vanda Pharmaceuticals USD 4.96M 4.96M Dec/2024